Jan P. Dutz

Dermatology & Skin Science

Degrees / Designations

MD, FRCPC

Email Address

jan.dutz@ubc.ca

Phone

604.875.4747

Mailing Address

UBC

Biography

Academic Appointment

Professor

Body Locations and Systems

Skin Conditions

Immune System

Dr. Dutz is the Coordinator of Resident Research for the UBC Department of Dermatology and Skin Science, and the focus of his laboratory has an independent laboratory is to study the skin immune system and its participation in autoimmune disease.

Clinical Trials

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Shingles

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional

Shingles

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriasis, Psoriatic Arthritis

News and Awards

Mar 2, 2018Seniors help seniors with new shingles vaccine trial

Search form

Jan P. Dutz

Biography

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)